| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Duchenne Muscular Dystrophy Research Center, University of California, Los Angeles, California
Previous investigations have shown that cytotoxic T lymphocytes (CTLs) contribute to muscle pathology in the dystrophin-null mutant mouse (mdx) model of Duchenne muscular dystrophy through perforin-dependent and perforin-independent mechanisms. We have assessed whether the CTL-mediated pathology includes the promotion of eosinophilia in dystrophic muscle, and thereby provides a secondary mechanism through which CTLs contribute to muscular dystrophy. Quantitative immunohistochemistry confirmed that eosinophilia is a component of the mdx dystrophy. In addition, electron microscopic observations show that eosinophils traverse the basement membrane of mdx muscle fibers and display sites of close apposition of eosinophil and muscle membranes. The close membrane apposition is characterized by impingement of eosinophilic rods of major basic protein into the muscle cell membrane. Transfer of mdx splenocytes and mdx muscle extracts to irradiated C57 mice by intraperitoneal injection resulted in muscle eosinophilia in the recipient mice. Double-mutant mice lacking dystrophin and perforin showed less eosinophilia than was displayed by mdx mice that expressed perforin. Finally, administration of prednisolone, which has been shown previously to reduce the concentration of CTLs in dystrophic muscle, produced a significant reduction in eosinophilia. These findings indicate that eosinophilia is a component of the mdx pathology that is promoted by perforin-dependent cytotoxicity of effector T cells. However, some eosinophilia of mdx muscle is independent of perforin-mediated processes.
This article has been cited by other articles:
![]() |
A. Demoule, M. Divangahi, G. Danialou, D. Gvozdic, G. Larkin, W. Bao, and B. J. Petrof Expression and Regulation of CC Class Chemokines in the Dystrophic (mdx) Diaphragm Am. J. Respir. Cell Mol. Biol., August 1, 2005; 33(2): 178 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wehling-Henricks, M. C. Jordan, K. P. Roos, B. Deng, and J. G. Tidball Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium Hum. Mol. Genet., July 15, 2005; 14(14): 1921 - 1933. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Moxley III, S. Ashwal, S. Pandya, A. Connolly, J. Florence, K. Mathews, L. Baumbach, C. McDonald, M. Sussman, and C. Wade Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society Neurology, January 11, 2005; 64(1): 13 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Kostek, J. A. Dominov, and J. B. Miller Up-Regulation of MHC Class I Expression Accompanies but Is Not Required for Spontaneous Myopathy in Dysferlin-Deficient SJL/J Mice Am. J. Pathol., March 1, 2002; 160(3): 833 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wehling, M. J. Spencer, and J. G. Tidball A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice J. Cell Biol., October 1, 2001; 155(1): 123 - 132. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |